login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
PHARVARIS NV (PHVS) Stock News
NASDAQ:PHVS - Nasdaq -
NL00150005Y4
-
Common Stock
- Currency: USD
22.68
-0.31 (-1.35%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PHVS Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Pharvaris N.V.
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
6 days ago - By: Pharvaris N.V.
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
19 days ago - By: Pharvaris N.V.
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
19 days ago - By: Pharvaris N.V.
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
a month ago - By: Pharvaris N.V.
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
a month ago - By: Pharvaris N.V.
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
a month ago - By: Pharvaris N.V.
Pharvaris Announces Annual Meeting of Shareholders
a month ago - By: Pharvaris N.V.
Pharvaris Announces Annual Meeting of Shareholders
2 months ago - By: Pharvaris N.V.
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
6 months ago - By: Pharvaris N.V.
Pharvaris Outlines 2025 Strategic Priorities
a month ago - By: Pharvaris N.V.
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
a month ago - By: Pharvaris N.V.
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
2 months ago - By: Pharvaris N.V.
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
2 months ago - By: Pharvaris N.V.
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
2 months ago - By: Pharvaris N.V.
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
2 months ago - By: Pharvaris N.V.
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
2 months ago - By: Pharvaris N.V.
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
3 months ago - By: Pharvaris N.V.
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3 months ago - By: Pharvaris N.V.
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
4 months ago - By: Pharvaris N.V.
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
4 months ago - By: Pharvaris N.V.
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
5 months ago - By: Pharvaris N.V.
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
5 months ago - By: Pharvaris N.V.
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
5 months ago - By: Pharvaris N.V.
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
5 months ago - By: Pharvaris N.V.
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
6 months ago - By: Pharvaris N.V.
Pharvaris Outlines 2025 Strategic Priorities
8 months ago - By: Pharvaris N.V.
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
8 months ago - By: Pharvaris N.V.
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
8 months ago - By: Pharvaris N.V.
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
8 months ago - By: Pharvaris N.V.
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
9 months ago - By: Pharvaris N.V.
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
9 months ago - By: Pharvaris N.V.
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
9 months ago - By: Pharvaris N.V.
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
9 months ago - By: Pharvaris N.V.
Pharvaris to Host Virtual Investor Event on October 23, 2024
Please enable JavaScript to continue using this application.